Drug intelligence / Profile preview

KRSA-028

Development stage: Preclinical
Lead developer: Korsana Biosciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

KRSA-028 is a next-generation shuttled monoclonal antibody being developed by Korsana Biosciences for the treatment of Alzheimer's disease. It selectively targets amyloid beta (Aβ) forms enriched in amyloid plaques. The drug utilizes the proprietary THETA™ (Therapeutic Targeting) platform, which incorporates transferrin receptor (TfR1) binding to facilitate transport across the blood-brain barrier and Fc engineering to attenuate effector function, thereby reducing the risk of amyloid-related imaging abnormalities (ARIA). Unlike currently approved intravenous treatments like lecanemab and donanemab, KRSA-028 is formulated for low-volume subcutaneous administration.

Targets

TFRC (Transferrin Receptor)

Beyond the preview

Go deeper on KRSA-028.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KRSA-028.

Explore the full profile